AnaSpec Introduces ClearPoint™ β-Amyloid Custom Peptides
Fremont, CA, May 12, 2010 --(PR.com)-- AnaSpec, the world’s largest provider of β-amyloid peptide and Alzheimer’s research reagents , has introduced its ClearPoint™ β-Amyloid custom peptide synthesis service. ClearPoint™ peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids.
ClearPoint™ peptides offer a choice of heavy hydrogen (2H), carbon (13C), or nitrogen (15N)-isotopes specifically labeled at single, multiple or universal positions. With triple-stage validation (both mass spec & HPLC) and over 10 years of successful synthesis, ClearPoint™ peptides are the proven solution for optimum quality heavy isotope labeled peptides.
These peptides can be used for the quantitative analyses of β-Amyloid peptides in biological fluids using mass spectrometry (MS). The inclusion of internal heavy isotope labeled peptide standards makes mass spectrometry an absolute quantitation (AQUA) method for the peptide of interest.1
β-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD). Historically, ELISA assays have been used in the quantitation of these peptides. However, technical challenges such as the tendency of β-Amyloid (1-40) and (1-42) peptides to self-aggregate, undergo post-translational modifications or bind to other proteins often result in inaccuracies in quantitation when using ELISA.2 Oe, et al. reported the use of [15N]-labeled β-Amyloid peptides as internal standards using immunoaffinity purified CSF.2
References
1. Harding, S. (ed.) 2007. Biotechnology & Genetic Engineering Reviews. Nottingham Univ. Press, Nottingham.
2. Oe, T. et al. Rapid Comm. Mass Spec. 20, 3723 (2006).
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
About Eurogentec
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liege, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com
###
ClearPoint™ peptides offer a choice of heavy hydrogen (2H), carbon (13C), or nitrogen (15N)-isotopes specifically labeled at single, multiple or universal positions. With triple-stage validation (both mass spec & HPLC) and over 10 years of successful synthesis, ClearPoint™ peptides are the proven solution for optimum quality heavy isotope labeled peptides.
These peptides can be used for the quantitative analyses of β-Amyloid peptides in biological fluids using mass spectrometry (MS). The inclusion of internal heavy isotope labeled peptide standards makes mass spectrometry an absolute quantitation (AQUA) method for the peptide of interest.1
β-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD). Historically, ELISA assays have been used in the quantitation of these peptides. However, technical challenges such as the tendency of β-Amyloid (1-40) and (1-42) peptides to self-aggregate, undergo post-translational modifications or bind to other proteins often result in inaccuracies in quantitation when using ELISA.2 Oe, et al. reported the use of [15N]-labeled β-Amyloid peptides as internal standards using immunoaffinity purified CSF.2
References
1. Harding, S. (ed.) 2007. Biotechnology & Genetic Engineering Reviews. Nottingham Univ. Press, Nottingham.
2. Oe, T. et al. Rapid Comm. Mass Spec. 20, 3723 (2006).
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
About Eurogentec
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liege, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com
###
Contact
AnaSpec, Inc.
Ping Yang
510-791-9560
www.anaspec.com
Ping Yang
510-791-9560
www.anaspec.com
Contact
Categories